Biocracked
Conceptual metaphor: a sheet of thick, clear laboratory glass standing upright, with a single hairline fracture running diagonally across it. A thin ribbon of vivid electric-green liquid seeps through the crack and drips onto a glossy white surface below. The glass is photographed straight on, at a slight low angle, in crisp macro focus along the fracture edges, where tiny chips catch the light. The backdrop is a seamless, saturated tomato-red field that fills the frame. Soft, directional studio light from the left creates bright refraction lines along the glass edge and a clean, warm-red tinted shadow on the right. The mood is tense but revealing, a long-held assumption starting to give way. Empty space on the right balances the composition. No text, no people, and no blue cast.
Longevity

Rapamycin 'Can't Reach the Brain'? Why That Myth Is Falling Apart

Dr. Synapse · · 4 min read

If you've spent any time in longevity circles, you've heard it: "Rapamycin doesn't get into the brain. It's not even in the spinal fluid." A new narrative review in the Journal of Alzheimer's Disease argues that this popular claim rests on a bad proxy, and that the evidence points the other way.

The catch: nobody has yet measured the parent drug directly in intact human brain tissue at the low doses longevity users take. More on that below.

Source: Melin JM, Young NA, Camardo J. "Beyond the cerebrospinal fluid: Preclinical and clinical evidence on central nervous system penetration and functional activity of oral rapamycin (sirolimus)." J Alzheimers Dis, 2026. PubMed | DOI

The "CSF misconception"

Rapamycin (sirolimus) is a potent inhibitor of mTORC1, a growth and nutrient-sensing pathway tied to aging biology. It is a leading candidate for age-related neurodegenerative disease. Yet many researchers assume it can't enter the brain, because it generally isn't detectable in cerebrospinal fluid (CSF).

The authors call this the "CSF misconception." Their argument is that failing to find a drug in CSF is not the same as failing to reach brain tissue.

Why rapamycin vanishes from CSF anyway

The review identifies four pharmacological reasons rapamycin is hard to detect in CSF, none of which means it's locked out of the brain:

  1. High lipophilicity. The drug is fat-loving and can be sequestered in brain parenchyma (the tissue itself) rather than floating in fluid.
  2. Extreme red-cell and protein binding. Very little drug stays free and measurable.
  3. P-glycoprotein efflux at the blood-CSF barrier. This pump pushes the drug back out at that specific interface.
  4. Assay insensitivity. Standard assays may simply be too insensitive to pick up the low concentrations present.

The conclusion: CSF concentration is "a flawed proxy" for how much rapamycin reaches the central nervous system.

The human evidence

The strongest direct data come from glioblastoma. Tissue sampling in these patients detected rapamycin in brain at concentrations sufficient to inhibit mTORC1. That is real human brain tissue, though it is tumor-affected tissue, not a healthy aging brain.

The review then lines up functional evidence that the drug is doing something in the brain:

  • Tuberous sclerosis complex (TSC): tumor regression and seizure control.
  • Alzheimer's disease: preservation of cerebral metabolism on PET imaging.
  • APOE4 carriers: increased cerebral blood flow.
  • Depression: prolonged antidepressant response.

The authors describe these effects as "incontrovertible activity in the brain." That is their interpretation. These are different populations, doses, and study designs, and the review is narrative rather than a systematic meta-analysis. Readers should treat the findings as converging clues, not a single proof.

The animal evidence (mice)

In mice, LC-MS/MS (a highly sensitive mass-spectrometry method) confirmed dose-dependent accumulation of rapamycin in brain. Rapamycin also modulated mTORC1 signaling, autophagy, and synaptic, epigenetic, and inflammatory pathways. This is preclinical work. Mouse brain data don't automatically translate to humans taking intermittent oral dosing.

The gap the authors admit

The review is candid about the central hole: direct measurement of parent drug in intact human brain parenchyma at therapeutic doses is lacking. The glioblastoma tissue data are the closest, but they involve a diseased brain and a specific clinical setting. So the honest summary is not "proven to reach healthy brains at longevity doses." It is "the claim that it can't reach the brain is poorly supported."

What this means for longevity users

The myth: "No CSF signal means no brain effect." The better reading: CSF is the wrong place to look. Tissue data, imaging, and clinical effects suggest rapamycin is active in the CNS.

Practical takeaways

  • Dose and timing: The review does not establish a dose or schedule for brain protection or longevity, and neither can this article. Any off-label regimen should be set with a physician who can monitor you.
  • Who this is relevant to: People following Alzheimer's and healthy-brain-aging research, and those weighing whether the "brain penetration" objection should rule rapamycin out. On this evidence, it shouldn't.
  • Who should be cautious or skip it: Rapamycin is a prescription immunosuppressant. People with active infections, those who are pregnant or trying to conceive, anyone with poor wound healing or surgery planned, and anyone with significant lipid or glucose issues should talk with a clinician first. Known side effects include mouth sores and metabolic changes. These are general drug-safety points, not findings of this review.
  • Don't self-treat: The review supports a mechanism, not a proven prevention strategy. Whether rapamycin prevents dementia in healthy people is still untested.

What researchers should do next

The authors recommend that Alzheimer's disease and related dementias (ADRD) trials stop leaning on CSF drug levels. Instead they should track:

  • Surrogate markers of mTORC1 inhibition
  • Functional neuroimaging
  • Clinical outcomes
  • ADRD fluid biomarkers

These pharmacodynamic measurements, they argue, are essential for designing and interpreting prevention trials in the aging brain.

Bottom line

"Rapamycin can't reach the brain" looks like an artifact of where people have been measuring. The evidence is suggestive and converging, but not yet definitive for healthy humans at longevity doses. Until direct brain measurements and prevention trials arrive, treat rapamycin as a promising, prescription-only, still-experimental option for the brain.

Full review: PubMed 42852863 | DOI: 10.1177/13872877261495936. This article is for information only and is not medical advice.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: D, bold color field.

A single brass pocket-scale balance sits at the center of a saturated mustard-yellow seamless backdrop, shot straight-on from slightly below at eye level. Its two pans hang almost perfectly level. One pan holds a small pile of pale, matte white powder, and the other holds a similar pile, so the tiny, nearly equal difference reads at a glance. A thin electric green thread is tied around the balance's pointer, a subtle accent. Soft, large-window studio light comes from the left and casts a crisp, short shadow to the right on the glossy surface below. Shallow depth of field blurs the background edges. The mood is quiet, skeptical and unresolved, with a clean, editorial look. No text, numerals or markings are visible on the scale.
longevity

Rapamycin Failed a Huge Human Longevity Test. Here's the Catch

BY DR. SYNAPSE ·

Rapamycin is the darling of the longevity world, but its biggest real-world human test just came back unimpressive. Among 4,885 kidney transplant patients on rapamycin and 6,589 who weren't, median survival age was 64.6 vs 64.3 years, a statistically similar result after adjustment. Over a median 11-year follow-up with 6,443 deaths, researchers saw no meaningful lifespan gain. But the study involved transplant patients on immunosuppressive regimens and was observational, so it can't settle whether low, intermittent dosing works in healthy people. Here's what it does and doesn't tell you.

Approach 1, macro science, with Palette D, bold color field. An extreme close-up, shot from a low three-quarter angle with a macro lens, of a single heaped tablespoon of concentrated tomato paste. The paste has a glossy, grainy texture with fine fibrous flecks and a small glistening swirl of olive oil on its surface. The spoon is brushed steel and sits against a saturated mustard-yellow backdrop. The tomato red against the yellow gives strong contrast. Hard but soft-edged studio light comes from the upper left, with crisp specular highlights on the paste and warm, slightly orange shadows, with no blue cast. The depth of field is shallow, so the background melts into smooth yellow. A tiny sprig of fresh basil in the blurred foreground adds a small green accent. The mood is vivid, energetic and curious, and it makes a humble ingredient look like a scientific specimen.
longevity

The Pantry Staple That Sharpened Middle-Aged Brains in 3 Months

BY NOVA CHEN ·

A cheap pantry staple may have nudged attention and mental speed upward in a new Barcelona trial of middle-aged adults. Over three months, people eating a measured daily dose of concentrated tomato paste scored higher on concentration (+7.2) and processing speed (+8.3) than on a lycopene-restricted diet. Brain imaging and a borderline BDNF bump hint at why, though the evidence is early. This article explains what 0.5 g/kg looks like in tablespoons, why olive oil makes sense, and why supplements weren't tested.

Approach: conceptual metaphor. Palette: bold color field.

A single steel bathroom-style analog tape measure, pulled taut and wrapped around a ripe, glossy yellow-orange pear lying on its side, with the tape's tip locked at the same unmarked point, suggesting a waistline that did not shrink. The pear sits on a saturated magenta seamless backdrop, shot from a low three-quarter angle with a shallow depth of field, the stem sharp and the background softly blurred. Hard but slightly diffused studio key light from upper left casts a crisp, short shadow in deeper magenta on the surface. A tiny electric green sticky dot marks the tape's end, with no numbers or writing visible. Mood: playful, skeptical, deadpan, scientific restraint rather than hype.
longevity

Weekly Rapamycin for a Year: Safe, But Did Visceral Fat Budge?

BY REX MERIDIAN ·

Everyone wants to know whether weekly rapamycin can shrink visceral fat and boost healthspan, and the PEARL trial has an answer that may surprise you. After 48 weeks in healthy adults, the primary endpoint of visceral fat did not budge, yet safety looked comparable to placebo. Some secondary signals, including lean mass and pain in women on 10 mg and better well-being on 5 mg, hint at benefits. But those are subgroup and self-reported findings, the drug was compounded, and no one has shown that it extends human lifespan. Here is what the data supports and what it does not.

Approach: conceptual metaphor. Palette: bold color field.

A single ripe, glossy red tomato-colored apple sits at the center of a saturated mustard-yellow seamless backdrop, with a neat row of five identical white capsules lined up beside it on the same surface. The apple is the clear winner of the frame. One capsule has rolled slightly away, cracked open and spilling a tiny pile of pale powder. Shot at a low three-quarter angle with a shallow depth of field, so the back capsules blur softly. Lighting is a large, soft key light from the upper left, giving crisp but gentle shadows with warm yellow bounce. A thin sprig of electric green (#00e676) leaves rises from the apple stem as the only green accent. Mood: confident, playful and skeptical, a clean verdict that real food outweighs pills. No text or labels.
longevity

Zombie Cell Supplements? 27 Human Trials Say Diet Beats Pills

BY NOVA CHEN ·

Supplement labels love to promise they'll "clear zombie cells," but a new systematic review of 27 human trials and 3,811 participants suggests the evidence is thin. Calorie restriction produced the most consistent drop in senescence-linked inflammatory signals. Omega-3 was the most promising supplement, though the evidence was limited and mixed. Telomere length and the classic p16/p21 markers mostly failed to move. Here's what that means for what you eat and what you buy.

This page is available in